With this model we discovered that antidiabetic SGLT2 inhibitors canagliflozin and dapagliflozin possess a clinically novel potentially atherosclerosis preventing mechanism of action: the allosteric activation of LCAT. This evidence concerns the gene SLC5A2 and atherosclerosis.